標(biāo)題: Titlebook: Management of Bladder Cancer; A Comprehensive Text Badrinath R. Konety,Sam S. Chang Book 2015 Springer Science+Business Media New York 2015 [打印本頁(yè)] 作者: Grievous 時(shí)間: 2025-3-21 19:58
書(shū)目名稱Management of Bladder Cancer影響因子(影響力)
書(shū)目名稱Management of Bladder Cancer影響因子(影響力)學(xué)科排名
書(shū)目名稱Management of Bladder Cancer網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱Management of Bladder Cancer網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱Management of Bladder Cancer被引頻次
書(shū)目名稱Management of Bladder Cancer被引頻次學(xué)科排名
書(shū)目名稱Management of Bladder Cancer年度引用
書(shū)目名稱Management of Bladder Cancer年度引用學(xué)科排名
書(shū)目名稱Management of Bladder Cancer讀者反饋
書(shū)目名稱Management of Bladder Cancer讀者反饋學(xué)科排名
作者: 斜 時(shí)間: 2025-3-21 22:41 作者: 有雜色 時(shí)間: 2025-3-22 02:27
Badrinath R. Konety,Sam S. ChangAuthored by experts in their respective fields.Provides a single, comprehensive reference source.Useful resource for physicians.Includes supplementary material: 作者: Vital-Signs 時(shí)間: 2025-3-22 04:49
http://image.papertrans.cn/m/image/622441.jpg作者: 放逐某人 時(shí)間: 2025-3-22 11:32 作者: 白楊魚(yú) 時(shí)間: 2025-3-22 12:54
Epidemiology and Natural Historyexposures, although differences in reporting may also play a role. In general, the incidence tends to be higher in developed countries than less developed ones. In all geographic regions, men are much more likely to be diagnosed with bladder cancer than women, and within each sex the risk of bladder作者: Painstaking 時(shí)間: 2025-3-22 18:32
Screening for Bladder Cancerved survival. While bladder cancer is the fourth most common cancer in men, overall the incidence of bladder cancer is too low to justify screening in the general population. Risk stratification based on known risk factors such as age, gender, smoking history, or occupational exposures may allow ide作者: Brain-Waves 時(shí)間: 2025-3-22 21:52
Pathology and Staging: Histopathology and Cytopathologypecimens, combined with use of urine cytology, is often optimal to render a diagnosis. In this chapter, we review a range of bladder findings, including normal, in situ, and invasive disease. Both conventional and non-conventional forms of bladder cancer are presented. Discussion of neoplastic mimic作者: 發(fā)酵劑 時(shí)間: 2025-3-23 01:35
Pathology and Staging: Genetics and Molecular Biologygenetic component in its development. Despite a twofold increase in incidence in first-degree relatives, a mode of inheritance, genetic site specificity, or an ethnic predilection has yet to be discovered. Specific chromosomal deletions, gene mutations, genetic pathways, epigenetic changes, and gene作者: decode 時(shí)間: 2025-3-23 09:35
Imaging in Localized and Advanced Bladder Cancerhere are many different imaging modalities (e.g. ultrasound, computed tomography, magnetic resonance imaging, positron emission tomography, bone scans), each with their specific applications. It is important to understand the merits of each modality to use them in the proper clinical setting. As the作者: anaphylaxis 時(shí)間: 2025-3-23 13:30
New Imaging Techniques in the Staging of Urothelial Carcinoma of the BladderAs such, staging is a key driver of therapy. While conventional imaging techniques clearly play a central role in the assessment of bladder cancer, assessment of disease extent could be improved. As such, multiple new imaging modalities have sought to improve staging and in doing so improve cure rat作者: inventory 時(shí)間: 2025-3-23 15:31 作者: jealousy 時(shí)間: 2025-3-23 21:56
Quality of Life Measureslife (HRQOL) is a subjective, patient-centric outcome that provides a more complete assessment of the impact of a disease or its treatment. HRQOL is a vital component when counseling and treating bladder cancer patients, and is also an important comparative-effectiveness research outcome. Although t作者: 吹牛者 時(shí)間: 2025-3-24 01:59
Prognostication and Risk Assessmentals. More than most other malignancies, urothelial carcinoma of the bladder cancer (UCB) is a highly aggressive and heterogeneous disease with high prevalence and disease recurrence rates. In patients with non-muscle invasive bladder cancer (NMIBC), prognosticators of outcomes and predictive tools p作者: propose 時(shí)間: 2025-3-24 05:02 作者: Flounder 時(shí)間: 2025-3-24 07:33
Improved Diagnostic Techniqueslance of patients with bladder cancer. Standard tools for diagnosis and staging incorporate the use of urine cytology and computer tomography to examine the upper tracts. Several urinary tumor markers may assist to identify and risk-stratify the probability of current and future (anticipatory) risk 作者: 啞巴 時(shí)間: 2025-3-24 10:53
Clinical Scenario: Microscopic Hematuria and Atypical Cytologyoscopic hematuria. Imaging (presumably a CT urogram) and cystoscopy did not identify an obvious tumor. He has three risk factors for urothelial cancer (UC): male, smoking history, and hematuria. The absence of a cytology that indicates “positive for cancer cells” is most important. Close follow-up b作者: 老人病學(xué) 時(shí)間: 2025-3-24 17:06
Localized Surgical Therapy and Surveillance cancer. The first part, surgical therapy, comprises preoperative assessment (including preoperative imaging studies, laboratory investigations, and antibiotic prophylaxis) followed by transurethral resection of bladder tumor. This section explores the principles of TURBT, including resection depth,作者: 擴(kuò)張 時(shí)間: 2025-3-24 20:41 作者: Callus 時(shí)間: 2025-3-24 23:23 作者: 問(wèn)到了燒瓶 時(shí)間: 2025-3-25 06:25
Clinical Scenario: Rapidly Growing, High Volume, Low-Grade Ta Tumor. The vast majority of these (>90 %) will be low grade. Although these tumors carry a low risk of progression to invasion (5–10 %) and an even lower risk of death (1–5 %), they have a very high likelihood of recurrence (50–70 %). Patients with large volume and rapidly recurring low-grade Ta bladder 作者: 世俗 時(shí)間: 2025-3-25 07:40
Clinical Scenario: Low-Grade T1 Tumorand without muscle present in the resected specimen. Some factors would suggest a good prognosis; some suggest a high risk for recurrence and progression. We discuss age, gender, and tumor size (or, as a possible surrogate, tumor weight) as prognostic factors. Furthermore, variability in grading and作者: 極肥胖 時(shí)間: 2025-3-25 13:08 作者: 敘述 時(shí)間: 2025-3-25 19:03
Ramdev Konijeti M.D.,Adam S. Kibel M.D.unter erheblichen Konkurrenz- und Preisdruck. Sie rechtfertigen h?here Preise mit einem Verweis auf eine hochwertige pers?nliche Beratung durch ihr Verkaufspersonal. Dies setzt allerdings eine entsprechend hohe Motivation und ein hohes argumentatives Leistungsverm?gen der Mitarbeiter voraus...Auf Ba作者: 和平主義 時(shí)間: 2025-3-25 23:00 作者: chastise 時(shí)間: 2025-3-26 03:39 作者: Ingenuity 時(shí)間: 2025-3-26 07:28 作者: congenial 時(shí)間: 2025-3-26 09:42 作者: 小步走路 時(shí)間: 2025-3-26 15:31
James S. Rosoff M.D.,Thomas E. Keane M.B., Ch.B., F.R.C.S.I., F.A.C.S.g, die in verdichteter und aufbereiteter Form dem Management für vielf?ltige Analyse- und Entscheidungszwecke zug?nglich gemacht werden. Hinzu kommen externe Informationen über das wichtige Umfeld der Unternehmung in Form von Markt- und Wettbewerbsinformationen, sowie die h?ufig sehr unstrukturierte作者: 發(fā)芽 時(shí)間: 2025-3-26 19:45
J. Alfred Witjes M.D., Ph.D.,Florine W. M. Schlatmann M.D. eines Software-Pakets dar, sondern ist ein anwendungsorientiertes Mensch-Maschine-System zur Befriedigung des Informationsbedarfs des Managements. Aus dieser Sicht ist das MIS ein Hilfssystem zur Unterstützung der Planungs- und Steuerungssysteme der Unternehmungen; es ist jedoch keineswegs mit dies作者: 閑逛 時(shí)間: 2025-3-26 23:03
Timothy Kim M.D.,Joshua G. Griffin M.D,Jeffrey M. Holzbeierlein M.D.,Wade J. Sexton M.D.nes Modells am Beispiel einer realen Einführung von Serviceentgelten. Die gewonnenen Erkenntnisse werden anschlie?end in konkrete Handlungsempfehlungen für die Unternehmenspraxis überführt..978-3-8349-1363-0978-3-8349-9983-2Series ISSN 2627-759X Series E-ISSN 2627-7603 作者: INCH 時(shí)間: 2025-3-27 02:53
Ramdev Konijeti M.D.,Adam S. Kibel M.D.nes Modells am Beispiel einer realen Einführung von Serviceentgelten. Die gewonnenen Erkenntnisse werden anschlie?end in konkrete Handlungsempfehlungen für die Unternehmenspraxis überführt..978-3-8349-1363-0978-3-8349-9983-2Series ISSN 2627-759X Series E-ISSN 2627-7603 作者: GUISE 時(shí)間: 2025-3-27 09:19
Christopher S. Gomez M.D.,Mark S. Soloway M.D.,Jorge Raul Caso M.D., M.P.H.,Claudia P. Rojas M.D.,Me Einsicht in die Personal- und Organisationsarbeit und den Umgang mit anderen Menschen“.; zur Erreichung dieser Ausbildungsziele sieht der Lehrplan eine bestimmte Anzahl von übungen vor; 3) die Spezialisierung bestimmt die letzte Stufe der undergraduate Ausbildung für Wirtschaftskr?fte;作者: NUDGE 時(shí)間: 2025-3-27 11:44
Manish I. Patel M.B.B.S., Ph.D., F.R.A.C.S.,Paul D. Sved M.B.B.S., M.S., F.R.A.C.S. Einsicht in die Personal- und Organisationsarbeit und den Umgang mit anderen Menschen“.; zur Erreichung dieser Ausbildungsziele sieht der Lehrplan eine bestimmte Anzahl von übungen vor; 3) die Spezialisierung bestimmt die letzte Stufe der undergraduate Ausbildung für Wirtschaftskr?fte;作者: Mawkish 時(shí)間: 2025-3-27 15:48 作者: Herd-Immunity 時(shí)間: 2025-3-27 20:52 作者: 言外之意 時(shí)間: 2025-3-27 22:26 作者: medieval 時(shí)間: 2025-3-28 05:01
J. Alfred Witjes M.D., Ph.D.,Florine W. M. Schlatmann M.D.em Management und dem automatisierten Subsystem (Computersystem) die Informationsprozesse (Problemfindung und Probleml?sung) ab, die die Grundlage der Planung und Steuerung bilden. Dabei liefert das automatisierte Subsystem des MIS die Informationen, die für die dem Manager übertragene(n) Phase(n) d作者: 混合,攙雜 時(shí)間: 2025-3-28 08:42 作者: 免除責(zé)任 時(shí)間: 2025-3-28 14:08 作者: 踉蹌 時(shí)間: 2025-3-28 14:56
Amber Mackey D.O.,Farnaz Hasteh M.D.,Donna E. Hansel M.D., Ph.D.作者: 欲望 時(shí)間: 2025-3-28 22:32
Christopher B. Anderson M.D.,David F. Penson M.D., M.P.H.,Daniel A. Barocas M.D., M.P.H.作者: 凌辱 時(shí)間: 2025-3-29 00:14 作者: 束縛 時(shí)間: 2025-3-29 05:38
Richard M. Bambury M.B., M.R.C.P.I.,Robert B. Sims,Jonathan E. Rosenberg作者: LURE 時(shí)間: 2025-3-29 08:56 作者: 顯赫的人 時(shí)間: 2025-3-29 11:24
Improved Diagnostic Techniquess promise in revealing subsurface microarchitecture information about bladder lesions in real-time, potentially leading to more accurate staging. Narrow-band imaging may augment standard endoscopic tools by providing increased contrast between normal and abnormal tissue on the basis of neovascularit作者: 騷擾 時(shí)間: 2025-3-29 17:20
Localized Surgical Therapy and Surveillanceas such as cystoscopy schedule, first cystoscopy, further cystoscopies, methods to improve surveillance cystoscopies, use of urinary markers, imaging and upper tract evaluation are discussed in more detail.作者: 實(shí)施生效 時(shí)間: 2025-3-29 22:03
Clinical Scenario: Rapidly Growing, High Volume, Low-Grade Ta Tumormotherapeutic agents are currently being investigated as intravesical therapies. Active surveillance with frequent office cystoscopy and fulguration of any small recurrences is also an option. In rare instances, patients who undergo grade or stage progression or those who fail to respond to the abov作者: Urologist 時(shí)間: 2025-3-30 03:01 作者: 最小 時(shí)間: 2025-3-30 07:12
Pathology and Staging: Histopathology and Cytopathologykers and utility of ancillary testing is incorporated when relevant. We conclude with an overview of cytology findings in bladder neoplasia and highlight the benefits and limitations of this diagnostic modality in bladder cancer.作者: 下級(jí) 時(shí)間: 2025-3-30 10:45 作者: 愛(ài)得痛了 時(shí)間: 2025-3-30 15:31
New Imaging Techniques in the Staging of Urothelial Carcinoma of the Bladderes. The focus of this chapter will be to highlight the current state-of-the-art with respect to use of newer magnetic resonance (e.g. diffusion-weighted MRI (DW MRI), dynamic contrast-enhanced MRI (DCE MRI), MRI lymphography) and positron emission tomography (PET) techniques to improve assessment of local and metastatic disease.作者: 圣人 時(shí)間: 2025-3-30 19:48
